Skip to content
The Policy VaultThe Policy Vault

guanfacine ER tablets (Intuniv, generic) — Medica

Attention Deficit Hyperactivity Disorder

Initial criteria

  • For Attention Deficit Hyperactivity Disorder: Approve for 1 year if the patient is age ≥ 6 years.
  • For Pervasive Developmental Disorders (e.g., autism spectrum disorder, Asperger’s disorder): Approve for 1 year if the patient has symptoms of attention deficit hyperactivity disorder (e.g., inattention, hyperactivity).

Approval duration

1 year